A plug-and-play platform of ratiometric bioluminescent sensors for homogeneous immunoassays by Ni, Yan et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2021-11-02 and may be subject to
change.
ARTICLE
A plug-and-play platform of ratiometric
bioluminescent sensors for homogeneous
immunoassays
Yan Ni 1,2,7, Bas J. H. M. Rosier 1,2,7, Eva A. van Aalen 1,2,7, Eva T. L. Hanckmann1,2, Lieuwe Biewenga1,2,
Anna-Maria Makri Pistikou 2,3, Bart Timmermans1,2, Chris Vu1,2, Sophie Roos1,2, Remco Arts1,2, Wentao Li4,
Tom F. A. de Greef 1,2,3,5, Marcel M. G. J. van Borren6, Frank J. M. van Kuppeveld 4, Berend-Jan Bosch 4 &
Maarten Merkx 1,2✉
Heterogeneous immunoassays such as ELISA have become indispensable in modern bioa-
nalysis, yet translation into point-of-care assays is hindered by their dependence on external
calibration and multiple washing and incubation steps. Here, we introduce RAPPID (Ratio-
metric Plug-and-Play Immunodiagnostics), a mix-and-measure homogeneous immunoassay
platform that combines highly specific antibody-based detection with a ratiometric biolu-
minescent readout. The concept entails analyte-induced complementation of split NanoLuc
luciferase fragments, photoconjugated to an antibody sandwich pair via protein G adapters.
Introduction of a calibrator luciferase provides a robust ratiometric signal that allows direct
in-sample calibration and quantitative measurements in complex media such as blood
plasma. We developed RAPPID sensors that allow low-picomolar detection of several protein
biomarkers, anti-drug antibodies, therapeutic antibodies, and both SARS-CoV-2 spike protein
and anti-SARS-CoV-2 antibodies. With its easy-to-implement standardized workflow, RAP-
PID provides an attractive, fast, and low-cost alternative to traditional immunoassays, in an
academic setting, in clinical laboratories, and for point-of-care applications.
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The widely recognized need for more personalized, patient-centered healthcare has urged the development of cheap,easy-to-use, yet reliable biomolecular diagnostics. Such
technology would not only accelerate biomolecular research in
academic and clinical environments but more importantly, allow
for fast diagnostic decision-making when access to clinical
laboratories is unavailable or cost-prohibitive. Affinity-based
immunoassays, such as ELISA and other heterogeneous immu-
noassays, form the cornerstone of today’s clinical bioanalytical
toolbox and offer both the specificity required to minimize
crosstalk and the modularity to allow the application to a broad
range of clinically relevant analytes. Translation of these immu-
noassays into point-of-care applications has proven challenging,
due to the requirement of multiple washing and incubation steps,
external calibration, and time-consuming optimization of sensor
surface immobilization and assay conditions1. Lateral flow
immunoassays (LFIAs) have been introduced as cheap and rela-
tively easy-to-use point-of-care tests, but they suffer from limited
sensitivity and are primarily used as qualitative tests2,3.
Single-step affinity-based detection assays performed directly
in solution could not only speed up traditional laboratory
immunoassays but would be particularly attractive for point-of-
care testing outside of the laboratory setting by non-expert
users4,5. Several promising optical biosensor platforms have been
reported that translate analyte binding directly into a con-
formational change, resulting in a change of signal intensity or
color6,7. Of these, sensors based on bioluminescence are parti-
cularly suited for measurements directly in complex media such
as blood with minimal sample handling, as they do not require
external excitation and therefore do not suffer from issues related
to autofluorescence or light scattering8,9. The Johnsson lab pio-
neered the development of semisynthetic sensor proteins
(LUCID) based on bioluminescence resonance energy transfer
(BRET) for the detection of small-molecule drugs such as
methotrexate and digoxin, and important metabolites such as
NAD+ and NADPH10–13. Alternatively, the LUMABS platform
was developed to enable the detection of specific antibodies
directly in blood plasma with the use of a smartphone
camera14–17. Both sensor platforms employ ratiometric biolumi-
nescent detection, which allows quantitative measurements and
enables integration in paper- and thread-based analytical devices
for low-cost point-of-care detection11,18,19. However, successful
development of LUCID and LUMABS sensors requires the
availability of suitable ligand-binding domains and ligand ana-
logs, or specific epitope peptides or mini-protein domains20,21,
respectively. Moreover, the change in emission ratio for these
sensors is typically two to fourfold14,17, and extensive protein
engineering is required to obtain sensors with a larger dynamic
range13.
Here, we present RAPPID (ratiometric plug-and-play immu-
nodiagnostics) as a comprehensive platform of ratiometric bio-
luminescent sensors that can be readily adapted to suit a very
broad range of biomolecular targets. RAPPID is based on the
complementation of antibody-conjugated split NanoLuc
luciferases22–25 to detect the formation of a sandwich immuno-
complex in solution with a high intrinsic signal-to-background
output (Fig. 1a). RAPPID does not require additional protein
engineering and uses protein G-mediated photoconjugation to
generate well-defined antibody conjugates directly from com-
mercially available antibodies26,27. In addition, we introduce a
green light-emitting calibrator luciferase as a simple method to
provide a robust blue-over-green ratiometric readout and direct
internal calibration. The ratiometric signal of RAPPID sensors is
stable over time and less sensitive to experimental conditions
such as temperature and substrate concentration, effectively
addressing this fundamental problem of intensiometric
bioluminescent assays. The ratiometric luminescent signal can be
recorded in a one-step assay in real-time with a standard digital
camera, highlighting the potential for point-of-care testing.
Development and implementation of a typical RAPPID assay
for a new biomolecular target is straightforward and consists of
three steps: (1) the selection of a pair of (commercial) antibodies
that bind the target analyte, (2) crosslinking of the antibodies to
the protein G-luciferase adapters using a simple one-hour illu-
mination protocol, and (3) addition of both antibody-luciferase
conjugates, the calibrator luciferase and the NanoLuc substrate to
the sample, followed by detection of the emission ratio of blue
over green light (Fig. 1a). In the case of antibody detection, the
dynamic range of the assay and its scope can be further increased
with an evolved set of RAPPID variants that use genetic fusions of
the split luciferase components to the antibody’s antigen. The
broad scope and excellent analytical performance of RAPPID are
demonstrated by developing assays for a range of clinically rele-
vant biomarkers, including cardiac troponin I, C-reactive protein
(CRP), three anti-drug-antibodies (ADAs), and two therapeutic
antibodies, displaying robust increases in emission ratio of up to
36-fold. RAPPID detection of CRP was validated using a com-
mercially available ELISA kit and in a clinical laboratory using 1-
µL patient plasma samples. Finally, we demonstrate that the
modularity of the RAPPID workflow enables prompt develop-
ment of immunoassays for emerging target analytes such as
SARS-CoV-2 spike proteins and anti-SARS-CoV-2 antibodies.
Results
Sensor design and characterization. To establish a universally
applicable sensing platform, we employed protein G-based pho-
toconjugation for the synthesis of sensor components. This
enables direct conjugation to most commercially available pri-
mary antibodies, obviating the use of labeled secondary anti-
bodies which increases complexity and can decrease the efficiency
of sandwich complex formation24. Both the 18-kDa large BiT
(LB) and the 1.3-kDa small BiT (SB) fragment of split NanoLuc
were genetically fused via a semi-rigid peptide linker to a protein
G adapter domain (Gx), carrying the photocrosslinkable non-
natural amino acid p-benzoylphenylalanine (Gx-LB and Gx-SB,
respectively, see Fig. 1b and Supplementary Fig. 5). A variant of
small BiT with Kd= 2.5 µM was chosen to ensure effective
complementation in the sandwich complex (vide infra)23.
Expression was performed in Escherichia coli with amber codon
suppression, using co-transformation with a plasmid containing
an engineered orthogonal aminoacyl tRNA synthetase/tRNA pair
(available from AddGene, for a step-by-step protocol see Supple-
mentary Information)28,29. Gx-LB and Gx-SB were obtained in
yields similar to standard protein expression after affinity chro-
matography purification (respectively ~18 mg/L and ~5mg/L, see
Supplementary Fig. 6).
Next, antibody conjugation was performed by illuminating
reaction mixtures with long-wavelength UV light (λ= 365 nm) in
phosphate-buffered saline (pH 7.4) for 1 h on ice, covalently
crosslinking Gx-LB and Gx-SB to the Fc-domain of the antibody.
SDS-PAGE analysis revealed a mixture of mono-conjugated, bi-
conjugated, and non-conjugated antibodies (Fig. 1b). Although
the conjugation efficiency can be further improved by increasing
the relative concentration of Gx-LB and Gx-SB, we typically chose
to use an equal molar ratio of protein to antibody to minimize the
presence of non-conjugated Gx-LB and Gx-SB, which could
contribute to non-specific background complementation. If
necessary, non-conjugated antibodies can be removed by small-
scale Ni2+-affinity chromatography, targeting the N-terminal
polyhistidine tag of Gx-LB and Gx-SB (Fig. 1b). Since protein G
binds to the majority of IgG-type antibodies, including all human
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and many other mammalian isotypes, this approach offers a
general method for the rapid synthesis of antibody-luciferase
conjugates from commercially available antibodies.
To establish proof of principle and characterize the perfor-
mance of the RAPPID sensor platform, we first developed a
sensor targeting cardiac troponin I (cTnI), an important protein
biomarker for a myocardial injury that requires highly sensitive
detection at picomolar concentrations (Fig. 2a)30. To this end,
Gx-LB and Gx-SB were photoconjugated to a pair of commer-
cially available anti-cTnI antibodies with distinct binding epitopes
(19C7 (mIgG2b) and 4C2 (mIgG2a), respectively, Fig. 1b).
Subsequently, increasing concentrations of cTnI were added to
a reaction mixture consisting of 1 nM of both antibody-luciferase
components and incubated for 30 min at room temperature
followed by the addition of NanoLuc substrate. A maximal 281-
fold increase in luminescence intensity was observed upon the
addition of cTnI, with a detection regime spanning four orders of
magnitude and a limit of detection of 4.2 pM (Fig. 2b and
Supplementary Table 2). Control experiments show that the low
background activity that is observed under these conditions in the
absence of analyte (<0.5%) is primarily caused by the residual
activity of uncomplemented LB and to a lesser extent by the
intrinsic affinity between split fragments LB and SB (Supplemen-
tary Fig. 8a). These initial results demonstrate that target binding
effectively stimulates NanoLuc complementation, resulting in a
sensitive bioluminescent signal output with a high signal-to-
background ratio.
The luminescent output follows a bell-shaped dose-response
curve, as evidenced by a decrease in signal at cTnI concentrations
>10 nM (Fig. 2b). This “hook” effect is well-known and occurs
because at high target concentrations the two sensor components
no longer bind to the same target to form an enzymatically active
ternary complex, but instead each bind to different target
molecules31,32. To provide a means for understanding and tuning
the response characteristics of the RAPPID sensor, we developed
a thermodynamic model that analyzes the equilibria involved in
the target-induced formation of the luminescent ternary complex
(Supplementary Fig. 1 and Supplementary Fig. 2). We investi-
gated critical parameters that can be used to modulate the sensor
response and performed nonlinear fitting of the experimental
data to the model (Fig. 2b). The model predicts that sensor
sensitivity and response are strongly dependent on the antibody
affinities and that the detection regime can be tuned by varying
the concentrations of antibody-luciferase conjugates (Supplemen-
tary Fig. 3a, c). We confirmed the latter predictions by
performing RAPPID assays at sensor component concentrations
of 10, 1, and 0.1 nM respectively (Supplementary Fig. 8b, c). An
additional parameter that affects sensor performance is the
intrinsic affinity between split NanoLuc components LB and SB.
As predicted by the model, attenuating the interaction between
LB and SB from Kd= 2.5 µM to Kd= 190 µM does not allow
effective luciferase complementation in the sandwich complex
(Supplementary Fig. 3b). Experimentally, increasing the strength
of the interaction (Kd= 0.28 µM) does not enhance luciferase
complementation much further in the presence of the analyte, but
does results in a higher background signal in the absence of
analyte and therefore a smaller dynamic range (Supplementary






































































Fig. 1 General overview and design elements of the RAPPID sensor platform. a Schematic representation of the concept of antigen detection using a
RAPPID sensor. A pair of primary antibodies is functionalized with a split version of the NanoLuc luciferase (large BiT and small BiT, respectively) through
the use of protein G-based photoconjugation. Antigen binding induces colocalization of the antibody pair and subsequent reconstitution of NanoLuc,
resulting in the emission of blue light upon conversion of the substrate (furimazine; λmax ~ 460 nm). Ratiometric detection is achieved by the addition of a
calibrator luciferase, consisting of a tight fusion of NanoLuc to fluorescent acceptor mNeonGreen, which produces a green signal (λmax ~ 520 nm) upon
substrate conversion through bioluminescent resonance energy transfer (BRET). The homogeneous solution-based assay is conducted by mixing the sample
and sensor components with the NanoLuc substrate and recording the emission spectrum. In the absence of antigen (left) no split complementation occurs
resulting in predominantly green emission from the calibrator luciferase (low blue/green ratio), while the presence of antigen (right) results in NanoLuc
reconstitution and an increase in blue-light emission (high blue/green ratio). b Schematic overview of the antibody conjugation method. Fusion between the
adapter protein G carrying the photoreactive non-natural amino acid p-benzoylphenylalanine and either large BiT or small BiT (Gx-LB and Gx-SB,
respectively) enables covalent coupling to the constant Fc-binding domain of most IgG-type antibodies, including all human IgGs, by exposure to long-
wavelength ultraviolet (UV) light (λ= 365 nm). Non-reducing SDS-PAGE analysis of the photoconjugation reaction (Rxn.) illustrates the successful coupling
of primary antibody (Ab, 10 µM) to either one (indicated with 1×) or two (2×) protein G adapters (10 µM). Reactions were performed in PBS (pH 7.4) for 1 h
on ice. Subsequent small-scale Ni2+-affinity chromatography removed unconjugated antibody (FT, flow-through) resulting in pure antibody conjugates
(Pur.). Gel image depicts a representative image from n= 3 independent experiments, with similar results. Source data is provided in Supplementary Fig. 9a.
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model can inform the behavior of RAPPID sensors and facilitate
the rational design of their molecular characteristics.
An inherent property of intensiometric luciferase assays is
depletion of the substrate over time and a concurrent decrease in
absolute signal intensity, which hampers reproducibility and
prohibits quantitative measurements. This is especially proble-
matic for point-of-care applications, where it is often difficult to
calibrate the assay and compensate for variations in substrate
concentration, as well as environmental conditions such as pH,
temperature, and ionic strength. We hypothesized that a
calibrator luciferase based on NanoLuc, but with a shifted
emission maximum, could be added to the sample together with
the sensor components to provide a direct internal calibration by
ratiometrically comparing two different emission wavelengths. To
construct the calibrator luciferase, we fused NanoLuc to the green
fluorescent protein mNeonGreen (mNG-NL), resulting in green
luminescent emission (λmax ~ 520 nm) due to efficient BRET
from NanoLuc to the fluorescent acceptor mNeonGreen33. The
calibrator was added to the cTnI sensor mixture at a final
concentration of 2 pM, after which luminescent spectra were
recorded at various cTnI concentrations (Fig. 2c). In contrast to
intensiometric detection, where the luminescent signal quickly
reached a maximum and then decayed, the ratiometric signal was
stable over a prolonged period of time, even at low substrate
concentrations (Fig. 2d and Supplementary Fig. 10). A similar
dose-response was observed, with a maximal signal at 10 nM cTnI
and a limit of detection of 19 pM (compare Fig. 2b, e). Although
the dynamic range is lower than in the intensiometric assay due
to spectral overlap between blue and green emission, the >25-fold
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Fig. 2 RAPPID enables robust ratiometric detection of cardiac troponin I (cTnI) in buffer and plasma and allows detection with a digital camera.
a Schematic illustration of the sensor components used for the detection of cTnI. All experiments were performed in technical triplicates with independent
preparations of the analyte, in buffer (PBS (pH 7.4), 0.1% (w/v) BSA), with 1 nM anti-cTnI (19C7) conjugated to Gx-LB, 1 nM anti-cTnI (4C2) conjugated to
Gx-SB, and 2 pM calibrator luciferase, unless indicated otherwise. Reaction mixtures were incubated for 30min at room temperature prior to the addition of
NanoLuc substrate and recording of the emission spectra. The blue/green ratio for ratiometric detection was calculated by dividing bioluminescent emission at
458 nm by emission at 518 nm. b Intensiometric sensor response curve for cTnI. RLU, relative luminescence units. Inset shows sensor response at low target
concentrations. Limit of detection (LOD) was determined at 4.2 pM with a maximal fold change of 281. An overview of all sensor characteristics including LOD
confidence intervals and Z′-factor statistical coefficients can be found in Supplementary Table 2. Experimental data were fitted to a thermodynamic model
(solid line, see Supplementary Fig. 4). c Bioluminescence spectra at various concentrations of cTnI in the presence of 2 pM calibrator luciferase. d Sensor
output over time for the experiments described in (b) (top, intensiometric) and (c) (bottom, ratiometric). Data in (c) and (d) are represented as mean ± sd. of
technical triplicates, with n= 3 independent preparations of the analyte. e Sensor response curve for increasing concentrations of cTnI. Blue/green ratios were
calculated from the spectra in (c), and show a 24-fold maximal increase in signal. The inset displays sensor behavior in the low-concentration regime as
indicated by the dashed rectangle, with a limit of detection (LOD) of 19 pM. f Bioluminescent emission does not require external excitation and therefore
enables detection with a conventional digital camera (Sony DSC-RX100) inside a box (left bottom). Photograph of the sensor response for increasing cTnI
concentration (right), taken 5min after addition of the NanoLuc substrate. g Response curve calculated from the photograph in (f) (top) and the correlation
between results from the plate reader and digital camera (bottom) for cTnI concentrations below 1 nM. A solid line indicates linear fit. Correlation analysis
yielded a Pearson correlation coefficient (r)= 0.996. h Sensor response in 100% (yellow) and 20% (gray, diluted in buffer) human blood plasma, recorded in
the plate reader. In (b), (e), (g), (h) individual data points are represented as circles, bars represent mean values, and dashed lines connect mean values. Data
represent technical replicates, with n= 3 independent preparations of the analyte. Source data are provided as a Source Data file.
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Table 2) and greater than those typically seen in BRET-based
sensors10,15. In addition, the calibrator concentration can be
adjusted in order to obtain an optimal response at the desired
detection regime of the analyte (Supplementary Fig. 11). In the
experiments reported so far, antibody-luciferase sensor compo-
nents were pre-incubated with the analyte to allow sufficient time
for complex formation, followed by the addition of substrate and
signal detection. The use of the calibrator luciferase additionally
allows for a one-step assay in which sensor components and
substrate are added simultaneously, and the formation of the
sandwich complex can be monitored in real-time using
ratiometric detection, even though the absolute intensity
decreases because of substrate turnover. As expected, the kinetics
of complex formation was found to depend on cTnI concentra-
tion, approaching equilibrium at ~60 min under these conditions
(Supplementary Fig. 12).
We also applied the ratiometric nature of the RAPPID sensor
to facilitate straightforward signal recording with a digital camera.
Using identical reaction conditions as described for Fig. 2c, the
cTnI concentration-dependent color change from blue to green
was clearly observed in images recorded with a standard digital
camera (Fig. 2f). The emission ratios were calculated from the
blue- and green-color channels of the RGB image and showed a
similar dose-response as in the plate reader assay, with a linear
correlation for cTnI concentrations ≤1 nM (Fig. 2e, g). Addi-
tionally, we assessed sensor performance in human blood plasma
and serum. The luminescent output signal was substantially
suppressed in 100% plasma, which can be partially attributed to
the absorption of blue light by hemoglobin and biliverdin (Fig. 2h
and Supplementary Fig. 13)34,35. Nevertheless, the high intrinsic
sensitivity of the RAPPID sensor still enabled ratiometric
detection, with a reliable >fivefold change in emission ratio in
both 20% blood plasma and serum (Fig. 2h and Supplementary
Fig. 14). These results establish the RAPPID sensor platform as a
robust ratiometric detection method with a large intrinsic
dynamic range. As a result, in-solution measurements can be
performed in clinically relevant media such as blood plasma,
while facile signal recording with a digital camera should enable
rapid diagnostic testing at the point of care.
Target modularity and clinical validation. To demonstrate that
the RAPPID workflow can be implemented for alternative targets,
we next developed a sensor for CRP, a pentameric protein with
clinical relevance as an inflammation marker in cardiovascular
disease36, COPD37, and infectious diseases (Fig. 3a). Two anti-
CRP antibodies (C135 and C6) were photoconjugated to Gx-LB
or Gx-SB, respectively, using similar conditions as described for
cTnI, and SDS-PAGE was used to confirm efficient conjugation
and purification (Supplementary Fig. 15). Using 1 nM of C6-LB,
10 nM C135-SB, and 2 pM calibrator luciferase and an incubation
time of 30 min before addition of the substrate, an 18-fold
increase in emission ratio was observed when varying the CRP
concentration in the pM–nM regime, with an LOD of 2.9 pM
(Fig. 3b). We confirmed complex formation within the incubation
time by monitoring the sensor response over time, which
demonstrated that a stable ratiometric signal was achieved rapidly
and, for high analyte concentrations, within 15 min (Fig. 3c and
Supplementary Fig. 16). We also used the CRP assay to assess the
effect of temperature on assay performance, which is an impor-
tant feature to consider when testing at the point of care. While
the absolute intensity of both the sensor and the calibrator luci-
ferase increased by 30–40% between 20 °C and 37 °C, the ratio of
the two signals, and thus the RAPPID sensor output, remained
stable in this temperature window (Supplementary Figs. 17
and 18).
Next, we benchmarked the analytical performance of RAPPID
to a commercially available high-sensitivity ELISA, used in
clinical care for cardiovascular risk assessment at low mg L−1
levels in human blood plasma (~8–80 nM)38,39. A linear
correlation (Pearson’s r= 0.996) was observed between CRP
concentrations as determined by ELISA and RAPPID (Fig. 3d and
Supplementary Fig. 19), confirming the accuracy of our CRP
sensor. Further validation was performed by comparing RAPPID
to an automated immunoturbidometric assay used in the clinic
for routine measurements of CRP as an inflammation marker in
blood plasma at high mg L−1 levels (~0.03–2.4 µM). Dilutions of
individual, freshly collected 1-µL patient plasma samples (total n
= 40) were measured using RAPPID and detected with a digital
camera. In parallel, samples from the same patients were
measured using the clinical assay (Fig. 3e and Supplementary
Fig. 20). Our results showed excellent linear correlation and a
small proportional difference with the clinical assay (Pearson’s r
= 0.993, slope 1.08 ± 0.02), and good reproducibility with an
average coefficient of variation of 8 ± 6% derived from technical
triplicates (Fig. 3f, g). Combined, these validation studies illustrate
that RAPPID enables the accurate determination of biomarkers in
a clinical setting. High assay sensitivity allows dilution of plasma
samples, which further reduces potential matrix effects and allows
tunable measurement of the analyte across a wide physiologically
relevant concentration range. In addition, the “mix-and-measure”
workflow substantially reduces total assay time and eliminates the
need for multiple wash steps, opening up possibilities for point-
of-care diagnosis.
Antibody detection using RAPPID. Our previously developed
LUMABS BRET sensor platform enables sensitive and quantita-
tive detection of specific antibodies but requires the genetic
incorporation of well-defined, high-affinity epitopes or mimi-
topes, which are not always available14. The RAPPID platform
provides assay formats for the detection of clinically relevant
antibodies with complex, discontinuous epitopes and for the
detection of heterogeneous antibody responses. We first devel-
oped sensors for ADAs, which are raised by the immune system
against therapeutic antibodies upon repeated administration and
are the main reason for rapid clearance40. We utilized our pho-
toconjugation strategy to directly couple both Gx-LB and Gx-SB
to three important clinical therapeutic antibodies: cetuximab
which targets EGFR and is used for colorectal cancer treatment41,
and adalimumab and infliximab which target TNFα and are
prescribed for a variety of autoimmune diseases42 (Fig. 4a and
Supplementary Fig. 21). Similar dose-response curves were
obtained for all three ADAs (Fig. 4b). Kinetic analysis revealed
that the addition of the calibrator luciferase is crucial for stable
sensor output and that a constant ratiometric signal is achieved
within 30 min after the addition of the substrate (Supplementary
Fig. 22). Because both antibody-luciferase conjugates contain the
same antibody that binds to the bivalent ADA target, a statistical
mixture is expected to form that also includes a fraction of non-
luminescent ternary complexes. Despite this, the RAPPID sensors
exhibited a robust, five to sixfold change in emission and LODs
between 59 and 81 pM (Supplementary Table 2).
Next, we applied RAPPID to detect antibodies that bind
structurally complex, discontinuous epitopes, employing it to
monitor therapeutic antibodies that target the TNFα homotrimer
as proof of concept42. TNFα-binding therapeutic antibodies, such
as adalimumab and infliximab, are widely administered anti-
inflammatory drugs for the treatment of diseases like rheumatoid
arthritis43 and inflammatory bowel disease44. Therapeutic drug
monitoring (TDM) of these antibodies is important in the clinic
to achieve optimal treatment efficiencies and to reduce possible
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side effects. We first applied the standard RAPPID format to
detect infliximab using two anti-infliximab-luciferase conjugates,
and a moderate three-fold change in emission was observed,
possibly due to the formation of non-productive complexes as
described above for the ADA sensors (Supplementary Fig. 23). To
overcome this issue, we implemented an alternative RAPPID
format by introducing a direct genetic fusion of SB to TNFα and
combined it with a Gx-LB-photoconjugated type-2 anti-antibody,
binding to the therapeutic antibody infliximab, or a type-3 anti-
antibody, binding to the complex of the target therapeutic
antibody adalimumab and TNFα (Fig. 4c and Supplementary
Fig. 24). Because of the relatively high cut-off values and trough
concentrations of adalimumab and infliximab45–48, assays were
performed using higher sensor concentrations (10 nM anti-
antibody-LB and 100 nM TNFα-SB). As a result, we observed
high substrate turnover and a quick decrease in luminescence
intensity within a few minutes after adding the NanoLuc
substrate (Fig. 4d). The addition of the calibrator luciferase was
therefore critical to allow accurate, time-independent antibody
quantification, which resulted in robust changes in emission ratio
in the clinically relevant therapeutic range, detected in diluted
blood plasma using either a plate reader or a digital camera
(Fig. 4e, Supplementary Figs. 25 and 26).
Kinetic experiments revealed that increasing the concentration
of TNFα-SB markedly decreased the time to reach stable sensor
output, from >30min to less than 15 min for detecting 1 nM
adalimumab or 1 nM infliximab (compare columns in Fig. 4f). At
the high sensor concentrations used for the assays described in
Fig. 4e (10 nM antibody-LB, 100 nM TNFα-SB), the formation of
the sandwich complex is complete even within 5 min (Supple-
mentary Figs. 25b and 26b). Collectively, these results illustrate
that the RAPPID platform is highly versatile and that the
standard assay format can be re-engineered to suit particular
applications related to antibody detection, including fast, one-step
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Fig. 3 Development and clinical validation of a RAPPID sensor for the detection of C-reactive protein (CRP). a Schematic illustration of the sensor
components used for the detection of CRP. All RAPPID assays were performed in technical triplicate with independent preparations of the analyte, with 1 nM
anti-CRP (C6) conjugated to Gx-LB, 10 nM anti-CRP (C135) conjugated to Gx-SB. Reaction mixtures were prepared in buffer (PBS (pH 7.4), 0.1% (w/v) BSA)
and incubated for 30min at room temperature prior to addition of NanoLuc substrate and recording of the emission spectra unless indicated otherwise. The
blue/green ratio was calculated by dividing emission at 458 nm by emission at 518 nm. b Sensor response curve for increasing concentrations of CRP,
displaying an 18-fold maximal increase in signal. Data points represent technical replicates, with n= 3 independent preparations of the analyte. c Sensor
output over time at various concentrations of CRP, as indicated in the graph. All components (sensor, calibrator, analyte, substrate) were added
simultaneously at t= 0. The dashed line indicates the 30-min. incubation time used in all other assays in this figure. Data are represented as mean ± sd of
technical triplicates, with n= 3 independent preparations of the analyte. d Correlation of CRP concentrations measured by ELISA and RAPPID. Samples were
prepared in diluted blood plasma and quantified using calibration curves obtained in buffer (see Supplementary Fig. 19). Error bars represent mean ± sd
(technical replicates, with n= 4 independent preparations of the analyte). The solid line indicates linear fit. Regression analysis yielded a Pearson’s
correlation coefficient (r)= 0.996. e Clinical validation was performed against an agglutination-based clinical CRP assay with a detection range of 4–304
mg/L (0.03–2.4 µM). For RAPPID assays, samples were diluted 1000-fold or 4000-fold in a buffer prior to incubation, and detection was performed using a
digital camera (for full method details, see Supplementary Fig. 20). The photograph shows the sensor output for eight patient plasma samples measured in
triplicate, with corresponding CRP concentrations as determined by the clinical assay in the histogram below. Bars and numbers represent mean values. f
Quantification of CRP levels in patient plasma, total n= 40. The graph shows CRP concentrations as determined by the RAPPID assay plotted against results
from the clinical assay. Values for the clinical assay represent the average of n= 2 independent measurements. For RAPPID, values represent the mean ± sd
of technical replicates from n= 3, wherein the patient samples were independently prepared. The solid line indicates a linear fit, with a slope of 1.08 ± 0.02
and Pearson’s r 0.993. Four samples yielded concentrations below the lower assay limit (<4mg/L) in both the clinical assay and RAPPID assay, these were
omitted in the statistical analysis. The underlying data are listed in Supplementary Table 3. g Bland–Altman analysis for the data described in (f). The solid
line represents the mean of bias between RAPPID and the clinical assay, dashed lines indicate the 95% limit of agreement (mean ± 1.96 × sd). Source data
are provided as a Source Data file.
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quantitative measurements of antibodies that bind discontinuous
epitopes and therapeutic antibodies and their ADAs.
RAPPID for SARS-CoV-2 antigen and antibody detection. The
modularity of the RAPPID platform is also attractive for the rapid
development of sensors for newly emerging targets. The COVID-
19 pandemic, caused by the SARS-CoV-2 virus, has highlighted
the need for fast, low-cost, point-of-care viral detection to
complement centralized PCR-based testing and vaccination49–52.
Two recently developed monoclonal antibodies53 that specifically
target the immunogenic spike glycoprotein of the SARS-CoV-2
virus allowed us to develop RAPPID sensors for viral antigen
detection. The antibodies (47D11 and 49F1) bind distinct epi-
topes on the spike protein which natively exists as a trimer. We
constructed two sensor variants, using either both antibodies
(heteropair, 47D11-LB with 49F1-SB) or only a single antibody
(homopair, 47D11-LB with 47D11-SB) and directly utilized them
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Fig. 4 RAPPID enables monitoring of clinically relevant antibodies. a Schematic overview of RAPPID sensors for the detection of anti-drug antibodies
(ADAs). The use of a commercially available therapeutic antibody conjugated to both Gx-LB and Gx-SB enables binding of the ADA and the formation of a
luminescent ternary complex. b Ratiometric sensor response curves in buffer (PBS (pH 7.4), 0.1% (w/v) BSA) of RAPPID sensors for anti-cetuximab, anti-
adalimumab, and anti-infliximab, respectively. c Schematic overview of RAPPID sensors for detection of therapeutic antibodies adalimumab and infliximab
using target antigen TNFα fused to SB, and the type 2 anti-infliximab and type 3 anti-adalimumab conjugated to Gx-LB. d Intensiometric detection of
infliximab without calibrator luciferase. Luminescent measurements were performed at various intervals following the addition of the NanoLuc substrate. e
Sensor response for adalimumab (left) and infliximab (right) detection in 10% plasma, diluted in the buffer. The same sample was used for detection with a
digital camera (top) and the plate reader (bottom). Gray boxes represent the clinically relevant concentration range of each therapeutic antibody from cut-
off value to trough concentration (8.5–53 nM and 3.3–47 nM for adalimumab and infliximab, respectively45–48), corrected for dilution. f Sensor response
over time after one-step incubation of all assay components for both adalimumab (top row) and infliximab detection (bottom row), with varying ratios
between sensor components antibody-LB and TNFα-SB, as indicated. Antibody-LB (1 nM) and TNFα-SB (1, 10, or 100 nM), therapeutic antibody (sample; 0,
0.1, or 1 nM), calibrator luciferase (cal.; 3–6 pM), and NanoLuc substrate (1000 × dilutions) were added simultaneously at t= 0. In (b), (d), (e) individual
data points are represented as circles, and dashed lines connect mean values. In (f) data are represented as mean ± sd. All experiments were performed in
technical triplicate, with n= 3 independent preparations of the analyte. Source data are provided as a Source Data file.
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for sensing the spike protein without further purification (Fig. 5a
and Supplementary Fig. 27). To scavenge non-conjugated Gx-LB
and Gx-SB and consequently reduce the background signal in
absence of the analyte, we added an excess of non-binding IgG to
the assay solution. We hypothesized that we could differentiate
between the monomeric and trimeric states of the spike protein,
the latter being more likely to represent the active virus, by
comparing the heteropair and homopair sensor response. Indeed,
only the heteropair sensor variant, in which the antibody-
luciferase conjugates are able to bind to distinct epitopes, exhib-
ited a dose-response to monomeric spike protein, while no
response was observed when using the homopair (Fig. 5b). Both
sensor variants showed a concentration-dependent increase in
emission ratio in response to the spike protein trimer, with a
detection regime ranging between 1 nM and 100 nM (Fig. 5c).
Model simulations suggest that the sensitivity could be further
improved by using antibodies with higher affinities (Supple-
mentary Fig. 3c). Indeed, when performing similar tests using
commercially available anti-spike antibodies with higher affi-
nities, the LOD could be decreased by almost an order of
magnitude, between 0.2 and 0.3 nM (Supplementary Fig. 28, 29
and Supplementary Table 2).
Containment of the ongoing pandemic and prevention of
future outbreaks also critically depends on the development of
serological assays as a tool to evaluate the extent of viral infection
in the population and assess the efficacy of vaccine candidates. As
such, we also developed a RAPPID variant for the detection of a
wide panel of antibodies against the SARS-CoV-2 virus54,55. In a
similar approach as described in the previous section, we adapted
the standard RAPPID assay format by introducing the immuno-
genic receptor-binding domain (RBD) of the SARS-CoV-2 spike
protein56, directly fused to either SB or LB (Fig. 5d). The bivalent
nature of antibodies promotes complementation of LB with SB,
hence producing a bioluminescent signal upon RBD-LB and
RBD-SB binding. After successful expression of RBD-LB and
RBD-SB in HEK293T cells and subsequent purification (Supple-
mentary Fig. 30), the sensor was assessed for its ability to detect
three different anti-RBD antibodies: a recently discovered
neutralizing antibody (47D11) and a commercially available
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Fig. 5 The RAPPID platform enables the detection of both the SARS-CoV-2 spike glycoprotein and anti-RBD antibodies. a Schematic overview of
RAPPID sensors for the detection of trimeric SARS-CoV-2 spike proteins. Recently discovered antibodies53,64 targeting distinct binding epitopes of the
immunogenic spike protein were used to generate sensors in either a heteropair or homopair setup. b, c RAPPID response curves in response to increasing
concentrations of monomeric spike protein (b) and native trimeric spike protein (c) using both the heteropair (gray) and homopair (red) configuration.
Photoconjugations were performed as described in Supplementary Fig. 27, and conjugation mixtures were used without further purification. A 200-fold
excess of cetuximab was added to suppress background luminescence. Experiments were prepared with 1 nM anti-spike (47D11) conjugated to Gx-LB and
10 nM anti-spike (49F1 for heteropair, 47D11 for homopair) conjugated to Gx-SB. Subsequently, experiments were performed in buffer (PBS (pH 7.4), 0.1%
(w/v) BSA) and incubated for 1 h at room temperature before addition of NanoLuc substrate and recording of the emission spectra. The blue/green ratio
was calculated by dividing bioluminescent emission at 458 nm by emission at 518 nm. d Schematic overview of RAPPID sensors for direct monitoring of
anti-virus antibodies against the receptor-binding domain (RBD) of SARS-CoV-2 spike protein. LB and SB were expressed as fusion proteins with the RBD,
enabling detection of all RBD-targeting antibodies. e Ratiometric sensor response curves for neutralizing antibody 47D11 (left)53, and commercially
available anti-spike D001 (center) and D003 (right)64. Insets show sensor response at low target concentrations, which allowed calculation of the limit of
detection, as indicated in the graphs. Experiments were performed with sensor and calibrator concentrations indicated in (d), prepared in buffer (PBS (pH
7.4), 0.1% (w/v) BSA), and incubated for 1 h at room temperature before addition of NanoLuc substrate. The fold increase is indicated in each graph.
Individual data points are represented as circles, while dashed lines connect mean values. All experiments were performed in technical triplicate, with n= 3
independent preparations of the analyte. Bars in histograms represent mean values. Source data are provided as a Source Data file.
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response curves of these antibodies, with LODs of 106 pM, 16 pM,
and 4 pM for 47D11, D001, and D003, respectively, and a maximal
change in emission ratio of 36-fold. As expected, the antibody
(49F1) that binds the spike protein outside the RBD53 did not
induce a sensor response (Supplementary Fig. 31). The ratiometric
detection enabled by the RAPPID assay is preferred over
intensiometric detection of split NanoLuc complementation57,58
as it allows quantitative measurements, which are important when
studying the time-dependence of the antibody response and the
correlation between antibody titers and immunological protection
(for kinetic analysis, see Supplementary Fig. 32)59,60. Taken
together, these results illustrate that the RAPPID platform allows
fast development of quantitative assays for newly arising targets
and that the modular design strategy enables multi-faceted viral
detection of both SARS-CoV-2 antigen and antibodies.
Protein-based biosensors that generate a bioluminescent signal
upon binding of a biomolecular target are attractive bioanalytical
tools because they (1) enable highly sensitive detection based on
enzymatic amplification, and (2) do not require external
excitation, which renders them ideal for direct homogeneous
detection in complex samples. In this study, we have established a
comprehensive sensor platform based on antibody-guided split
NanoLuc complementation combined with robust ratiometric
output. The RAPPID platform is highly modular and broadly
applicable as it allows the use of commercially available
monoclonal antibodies as recognition elements. The required
protein G-split NanoLuc fusion proteins are easily expressed in E.
coli and obtained using standard affinity purification, while
antibody conjugation is based on a one-hour illumination
protocol that does not require expert laboratory equipment.
Moreover, the use of a calibrator luciferase enables single-step,
ratiometric detection of immunocomplex formation in real-time
by monitoring the blue-to-green color change using a standard
digital camera.
Combining these design aspects allowed the formulation of a
straightforward workflow for developing in-solution immunoas-
says with low-pM sensitivity, high signal to noise, a large dynamic
range, and excellent reproducibility for any relevant target,
depending only on the availability of a suitable pair of antibodies.
Sensors for traditional biomarkers such as cardiac troponin I and
CPR, as well as newly emerging targets such as the SARS-CoV-2
virus, could be developed within days after antibody arrival.
Depending on the affinity of the antibodies and the target
architecture, robust changes in emission ratio ranging from 5 (for
ADAs) to 25 were routinely obtained. The semi-flexible linkers
that were employed are based on previous luminescent sensors
and are known to effectively bridge the 10–15-nm distances
encountered in sandwich immunoassays, and RAPPID assays
were successfully developed for all antigens tested so far,
representing a wide variety of architectures. Nonetheless,
depending on the architecture of the sandwich complex,
optimization of linker length and stiffness could be employed
to further improve complementation efficiency for specific
targets. Real-time monitoring enabled by the calibrator luciferase
revealed that, as expected for a homogeneous assay, the kinetics of
complex formation is affected by the concentrations of both the
target and the antibody conjugates. However, in most cases, assay
times of 15–30 min were sufficient to allow reliable quantification.
Finally, the sensor’s responsive range can be rationally adjusted to
a specific application by varying the concentration of the antibody
conjugates and the concentration of the calibrator luciferase.
The platform is versatile by design, which allowed us to create
re-engineered RAPPID variants and multi-faceted detection
assays, for example for measuring therapeutic antibodies and
their anti-drug antibodies, as well as both SARS-CoV-2 antigens
and antibodies. Additionally, the antibody-based sensor
components allow detection of targets with complex or
discontinuous epitopes, which represents an important advantage
compared to other bioluminescent sensors such as the LUMABS
platform. A key aspect of the RAPPID platform is direct in-
sample calibration by the addition of a calibrator luciferase that
contains an identical luciferase domain but with a spectrally
distinct emission profile. We took advantage of these features by
developing assay variants for the detection of anti-TNFα and
anti-RBD antibodies, in which either one or both parts of the split
luciferases were genetically fused to TNFα and RBD, respectively.
Similar approaches for the detection of anti-RBD antibodies were
recently reported57,58. Although the ratiometric response is
smaller than the reported intensiometric response, the use of a
calibrator luciferase ensures that the ratiometric output signal is
stable over time and less susceptible to experimental variation,
rendering our assay more suitable for antibody quantification. We
envision that the use of a calibrator luciferase can be applied as a
general strategy to translate intensiometric luminescent assays
into robust ratiometric assays with a time-independent and
quantitative assay output. As such, other recently developed
intensiometric sensors based on split luciferase complementation
could benefit from a calibrator luciferase to further enhance their
potential in a clinically relevant environment21,58,61. Further-
more, the concept can be extended by using different acceptor
domains, such as quantum dots, organic fluorophores, or
fluorescent protein domains, with a larger spectral separation
from the blue light-emitting NanoLuc.
Ratiometric detection is also an important prerequisite for the
successful application of bioluminescent assays in point-of-care
diagnostics. Direct comparison of RAPPID with a commercially
available ELISA kit and an automated clinical assay demonstrated
that the blue-to-green ratiometric sensor signal can be detected
fast and robustly with minimal equipment and low sample
volumes while mirroring the clinically approved assays in terms
of accuracy and sensitivity. In addition, implementation at the
point of care can be envisioned by the integration of the
bioluminescent sensor proteins into paper- or thread-based
analytical devices11,19. To increase the sensitivity of such devices,
RAPPID could also be combined with dedicated microfluidic
devices, while dedicated readers could be developed that capture
the bioluminescent light more efficiently than commercial digital
or smartphone cameras62. A possible limitation of the current
RAPPID assays for point-of-care applications is the limited long-
term stability of sensor components at room temperature, in
particular for the NanoLuc substrate. However, this could be
addressed by packaging devices under low-oxygen conditions, or
by applying a recently reported formulation of an all-in-one
reagent that has a long shelf life at ambient temperatures25.
In conclusion, RAPPID represents an attractive immunoassay
format for point-of-care diagnostics, that combines the analytical
performance of a laboratory-based immunoassay such as ELISA
with the speed and ease of use of LFIAs. The possibility to
integrate ratiometric bioluminescent assays such as RAPPID with
(paper-based) microfluidic devices and the ability to develop a
RAPPID assay for a new target analyte only within days, makes
RAPPID an attractive immunoassay format for a broad spectrum
of applications, including rapid screening methods, therapeutic
antibody-drug monitoring, and the rapid detection of infectious
diseases to be better prepared for future pandemics.
Methods
Cloning. The pET28a(+) vectors containing DNA encoding for Gx-SB, Gx-LB,
calibrator luciferase (mNG-NL), and SUMO-TNFα-SB were ordered from Gen-
Script. The sequence of calibrator luciferase was reported by Suzuki et al.33, and a
His-tag at the N-terminus and a Strep-tag at the C-terminus were included to
facilitate purification27. Site-directed mutagenesis to change SB sequences was
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carried out using the QuikChange Lightning Site-Directed Mutagenesis kit (Agilent
technologies) and specifically designed primers (Supplementary Table 1).
The RBD of the SARS-CoV-2 Spike glycoprotein (produced under
HHSN272201400008C and obtained through BEI Resources, NIAID, NIH: Vector
pCAGGS Containing the SARS-Related Coronavirus 2, Wuhan-Hu-1 Spike
glycoprotein RBD, NR-52309) was genetically fused to either the LB or SB via a
semi-flexible linker and subsequently cloned into the pHR-CMV-TetO2_3C-
mVenus-Twin-Strep plasmid, a gift from A. Radu Aricescu (Addgene plasmid
#113891)63, by means of restriction-ligation approach. Snapgene 5.2.4 software was
used for cloning design and sequence verification.
All cloning and mutagenesis results were confirmed by Sanger sequencing
(BaseClear). The DNA and amino acid sequences of the fusion proteins are listed in
the supplementary information (Supplementary Fig. 33–38).
Protein expression. The pET28a plasmid encoding for either Gx-LB or Gx-SB was
co-transformed into E. coli BL21 (DE3) together with a pEVOL vector encoding a
tRNA/tRNA synthetase pair in order to incorporate para-benzoyl-phenylalanine
(pBPA)28. The pEVOL vector was a gift from Peter Schultz (Addgene plasmid #
31190). Cells were cultured in 2YT medium (16 g peptone, 5 g NaCl, 10 g yeast
extract per liter) containing 30 μg/mL kanamycin and 25 μg/mL chloramphenicol.
Protein expression was induced using 0.1 mM IPTG and 0.2% arabinose in the
presence of 1 mM pBPA (Bachem, F-2800.0001). Following overnight expression at
20 °C, cells were harvested by centrifugation at 10,000 g for 10 min and lysed using
the Bugbuster reagent (Novagen) and Benzonase (Novagen). Proteins were purified
using Ni2+ affinity chromatography followed by Strep-Tactin purification
according to the manufacturer’s instructions. Correct incorporation of pBPA was
confirmed by Q-ToF LC-MS (WatersMassLynx v4.1), using MagTran v1.03 for MS
deconvolution (Supplementary Fig. 7).
The pET28a plasmid encoding the calibrator luciferase fusion protein was
transformed into E. coli BL21 (DE3). Cells were cultured in LB medium (10 g
peptone, 10 g NaCL, 5 g yeast extract per liter) containing 30 μg/mL kanamycin.
Protein expression was induced using 0.1 mM IPTG at 20 °C overnight. The
harvested cells were lysed using the Bugbuster reagent and Benzonase. Proteins
were purified using Ni2+ affinity chromatography and Strep-Tactin purification.
The SARS-COV-2 spike trimer protein was expressed transiently in HEK-293T
cells with a C-terminal trimerization motif and Strep-tag using the pCAGGS
expression plasmid and purified from the culture supernatant by Strep-Tactin
chromatography53. Similarly, the SARS-COV-2 spike monomer was expressed with
a C-terminal Strep-tag and purified by Strep-Tactin chromatography53.
The pET28a plasmid encoding SUMO-TNFα-SB fusion protein was transformed
into E. coli BL21 (DE3). Cells were cultured as described above. The harvested cells
were resuspended in Tris-HCl Buffer (40mM, pH 8.0, containing 125mM NaCl
and 5mM imidazole) and Benzonase. Cell disruption was then performed by
ultrasonication on ice with 5 pulses of 20 s and an amplitude of 50%. After
centrifugation, proteins were purified from the supernatant at 4 °C, using Ni2+
affinity chromatography. The His-SUMO-tag was cleaved from TNFα-SB by adding
1:1000 (v/v) SUMO protease into the protein solution which was further dialyzed in
Tris-HCl buffer (20mM, pH 8.0, containing 150mM NaCl and 1 mM DTT)
overnight, at 4 °C. Cleaved TNFα-SB was obtained using Ni2+ affinity
chromatography to remove the cleaved His-SUMO-tag.
Lentiviral production of the two vectors, encoding either the RBD-LB or RBD-
SB transgene, and subsequent protein expression was performed according to
standard protocols as described in ref. 63. Briefly, HEK293T cells (ATCC® CRL-
3216™) were transiently co-transfected with the abovementioned transfer vectors, as
well as the VSV-G envelope (pMD2.G) and packaging plasmids (pCMVR8.74).
Plasmids pMD2.G and pCMVR8.74 were gifts from Didier Trono (Addgene
plasmid #12259 and Addgene plasmid #22036, respectively). HEK293T cells were
then infected in order to establish polyclonal stable cell lines via the integration of
the lentiviral genetic elements into the cell genome. Cells were routinely cultured
under standard culturing conditions (37 °C, 5% CO2, 95% air, and 95% relative
humidity) in Dulbecco’s Modified Eagle Medium (DMEM 21885-025,
ThermoFisher), supplemented with 10% Fetal Bovine Serum (FBS). For cell line
maintenance, cells were split at a ratio of 1:5-1:10, upon reaching confluency.
Protein expression was induced by the addition of 1 μg/mL doxycycline (D3447,
Merck) in DMEM, supplemented with 2% FBS. Successful transduction of cells was
monitored by fluorescence imaging of the reporter protein mVenus, ensuing
induction. Protein-containing medium was harvested 4–5 days following induction
and protein was purified by Strep-Tactin affinity chromatography. All the purified
proteins were snap-frozen and stored at −80 °C until use.
Photoconjugation. Cardiac Troponin I antibodies 19C7 (4T21) and 4C2 (4T21),
and CRP antibodies C6 (4C28cc) and C135 (4C28) were obtained from Hytest.
Therapeutic antibodies cetuximab and infliximab were obtained via the Catherina
hospital pharmacy in Eindhoven and Maxima Medisch Centrum pharmacy in
Veldhoven, the Netherlands, respectively. Adalimumab (A1048-100) was obtained
from Gentaur. Anti-adalimumab/TNFα monoclonal antibody (HCA207) and anti-
infliximab (HCA213) were obtained from BioRad. The cDNA encoding the anti-
SARS-COV-2 antibodies 47D11 and 49F1 were cloned into expression plasmids
with human IgG1 heavy chain and Ig kappa light chain constant regions (Invi-
voGen), containing the interleukin-2 signal sequence to facilitate secretion of the
antibodies. Subsequent transfection and expression were performed according to
ref. 53 and protocols from InvivoGen in HEK-293T cells and purified using Protein-
A affinity chromatography. Commercially available anti-SARS-COV-2 D001, D002,
D003, and D004 were ordered from Sino Biological. Photoconjugation reactions
were performed using a Promed UVL-30 UV light source (4 × 9W). Samples
containing antibody and Gx-LB or Gx-SB in PBS buffer (pH 7.4) were illuminated
with 365 nm light for 30–180min. The samples were kept on ice during photo-
conjugation. If necessary, the photoconjugated products were further purified using
Ni-NTA spin columns (ThermoFisher) followed by PD G10 desalting columns (GE
Health) according to the manufacturer’s instructions. Antibody-conjugates were
stored at 4 °C or −80 °C until use. Uncropped and unprocessed SDS-PAGE gels can
be found in the Supplementary Information or in the Source Data file.
Luminescent assays. Cardiac Troponin I (8T53) and CRP (8C72) were purchased
from Hytest. Anti-cetuximab (HCA221), anti-infliximab (HCA213G) and anti-
adalimumab (HCA205) were ordered from BioRad. Intensiometric assays were
performed at sensor protein concentrations of 0.1–10 nM in a total volume of 20 µL
PBS buffer (pH 7.4, 0.1% (w/v) BSA) in PerkinElmer flat white 384-well Optiplate.
Measurements in diluted blood plasma and serum were performed by preparing
the analytes in pooled human blood plasma (in ACD, DivBioScience) and human
serum (male AB, Sigma Aldrich) and sensor proteins in PBS buffer (pH 7.4, 0.1%
(w/v) BSA). After incubation of sensor proteins and analytes for 5–60 min,
NanoGlo substrate (Promega, N1110) was added at a final dilution of 250–1000-
fold. Luminescence intensity was recorded on a Tecan Spark 10M plate reader with
an integration time of 100 ms and data was collected using Tecan SparkControl
v2.1. For ratiometric assays, an appropriate amount (0.5–50 pM) of calibrator
luciferase was added into the samples and luminescence spectra were recorded
between 398 nm and 653 nm with a step size of 15 nm, a bandwidth of 25 nm, and
an integration time of 1000 ms. The blue/green ratio was calculated by dividing
bioluminescent emission at 458 nm by emission at 518 nm. LOD and 95% con-
fidence interval of the LOD were calculated in Microsoft Excel by linear regression
of the response related to the analyte concentration for a limited range of con-
centrations (for an overview, see Supplementary Table 2).
The luminescence signal was also recorded by using a SONY DSC-RX100
digital camera. The plate was placed into a Styrofoam box to exclude the
surrounding light. The pictures were taken through a hole in the box using the
digital camera with exposure times of 10–30 s, F value of 1.8, and ISO value of
1600–6400. Method details of the clinical validation of the CRP-RAPPID assay can
be found in Supplementary Fig. 20. CRP detection in the clinic was performed in
plasma using an Atellica latex-enhanced immunoturbidometric assay (random-
access analyzer, Siemens Healthcare Diagnostics Inc. USA), which uses latex
particles coated with anti-CRP antibodies that rapidly agglutinate in the presence
of CRP, increasing the intensity of scattered light. The assays were performed
according to routine protocols in the laboratory of clinical chemistry at the
Rijnstate hospital in Arnhem, The Netherlands.
Material availability. Plasmids for recombinant expression of Gx-LB, Gx-SB,
RBD-LB, RBD-SB, TNFα-SB, and calibrator luciferase mNG-NL will be made
available through AddGene after publication. Protein and DNA sequences are
available in the Supplementary Information. Antibodies 47D11 and 49F1 and the
SARS-CoV-2 spike protein variants used as analytes are available upon request as
specifically outlined in ref. 53.
Ethics declaration. All patient samples were obtained under protocols and
guidelines approved by the local ethical committee of the Rijnstate Hospital
(reference number: KCHL 2021-1790) and in accordance with the Declaration of
Helsinki, and de-identified before use. All patients provided informed consent, and
only samples were used in which CRP was ordered as part of standard clinical care
and of patients who did not object against usage of their remnant blood for quality
purposes.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data generated to support the plots and findings within this study, including all raw
luminescence data, are provided in the Source Data files with this paper. Source data are
provided with this paper.
Code availability
Custom-written code for the computer models and simulations that support the
experimental findings in this study is available as Supplementary Software.
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